Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux

CAROZZO, ALEJANDRO; YANEFF, AGUSTÍN; GÓMEZ, NATALIA; DI SIERVI, NICOLÁS; SAHORES, ANA; DIEZ, FEDERICO; ATTORRESI, ALEJANDRA I.; RODRÍGUEZ-GONZÁLEZ, ÁNGELA; MONCZOR, FEDERICO; FERNÁNDEZ, NATALIA; ABBA, MARTÍN; SHAYO, CARINA; DAVIO, CARLOS

MOLECULAR PHARMACOLOGY

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS

Lugar: Baltimore; Año: 2019 vol. 96 p. 13 - 25

0026-895X

Pancreatic cancer is one of the most lethal types of tumors with no effective therapy available; is currently the third leading cause of cancer in developed countries; and is predicted to become the second deadliest cancer in the United States by 2030. Due to the marginal benefits of current standard chemotherapy, the identification of new therapeutic targets is greatly required. Considering that cAMP pathway is commonly activated in pancreatic ductal adenocarcinoma (PDAC) and its premalignant lesions, we aim to investigate the multidrug resistance-associated protein 4 (MRP4)-dependent cAMP extrusion process as acause of increased cell proliferation in human PDAC cell lines. Our results from in silico analysis indicate that MRP4 expression may inf